Now This Growth Stock Is Getting Attractive

Jamieson Wellness Inc. (TSX:JWEL) is a great growth stock opportunity after shaving off about 30% from its high.

| More on:
growing dividends

Jamieson Wellness (TSX:JWEL) stock has corrected about 15% since it reported its third-quarter results last Tuesday. However, the stock was actually weak earlier than that. Specifically, after it peaked in late September, the stock has lost about 30% of its value from about $27 to below $19 per share.

fruits, groceries

The business

Jamieson manufactures, distributes, and markets branded natural healthcare products, including vitamins, minerals, and supplements.

It has a number one position in Canada with a market share of 25% at food, drug, and mass stores, such as Superstore and London Drugs.

Jamieson operates in two business segments. Its branded segment offers a diversified range of premium products across multiple distribution channels. Last year, this segment contributed to 79% of revenue and 86% of adjusted EBITDA.

Its strategic partners segment are co-manufacturing partnerships with select blue-chip consumer health companies and retailers around the world, aiming to leverage infrastructure and reduce costs. Last year, this segment contributed to 21% of revenue and 14% of adjusted EBITDA.

Q3 results

Here are some key metrics compared to the same period in 2017:

Q3 2017 Q3 2018 Change
Revenue $80.1 million $83.1 million 3.7%
Earnings from operations $11.3 million $12.7 million 12.5%
Adjusted net income $7.8 million $8.9 million 13.6%
Adjusted EBITDA $16.1 million $17.9 million 10.7%
Adjusted diluted earnings per share $0.20 $0.22 13.6%

I showed adjusted metrics above because there were public offering costs of $2.6 million that was recorded in Q3, for example. These are costs related to the initial public offering that occurred in 2017. In the first nine months of this year, Jamieson recorded $9.5 million of such costs. The adjusted metrics should give a better picture of Jamieson’s profitability.

Year over year, Jamieson’s gross profit margin and operating margin improved from 33% to 33.2% and 14.1% to 15.3%, respectively.

Jamieson’s nine-month results

Here are some key metrics compared to the same period in 2017:

Q1-Q3 2017 Q1-Q3 2018 Change
Revenue $216.3 million $230.3 million 6.5%
Earnings from operations $30 million $33 million 10%
Adjusted net income $17.8 million $21.5 million 20.7%
Adjusted EBITDA $42.6 million $44.7 million 4.8%
Adjusted diluted earnings per share $0.45 $0.54 20.7%

Year over year, Jamieson’s gross profit margin and operating margin improved from 34.2% to 34.4% and 13.9% to 14.3%, respectively. Also notable is that its number of outstanding shares remained constant, which is a positive.

Recent international growth developments

Jamieson products are available in more than 40 countries around the world. Recently, Jamieson made advancements in its growth strategy in China. Instead of only selling its products via an online store, it obtained the right to sell in physical stores as well. It’s also setting up an office and warehouse in Shanghai.

Furthermore, after signing a five-year partnership agreement, Jamieson’s products will begin selling this month in MedPlus, India’s second-largest pharmacy chain. MedPlus has 1,500 retail locations and plans to more than triple its locations by 2023.

Investor takeaway

Jamieson is a growth stock, and it has been priced at high multiples since its initial public offering. It has mostly traded at a price-to-earnings multiple (P/E) in the 30s. At $18.75 per share, the company is much more attractive for double-digit growth at an estimated 2018 P/E of about 21.8.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Kay Ng has no position in any of the stocks mentioned.

More on Investing

Aircraft wing plane
Coronavirus

Air Canada (TSX:AC) Stock: Ready to Take Off?

While Air Canada is handling what it can control really well, there are many worsening macro headwinds that will likely…

Read more »

stock analysis
Stocks for Beginners

2 Simple Strategies That Canadian Investors Can Use to Start Investing in Stocks

Here are two of the simplest and best investing strategies for Canadians to start investing in stocks today.

Read more »

A miner down a mine shaft
Metals and Mining Stocks

3 Mining Stocks to Buy Amid Rising Inflation

The Canadian inflation rate came in at 6.8% for April — the highest in 31 years. The prices of petroleum…

Read more »

edit Four girl friends withdrawing money from credit card at ATM
Bank Stocks

Bank Earnings: Did TD Stock or Royal Bank Come Out on Top?

TD (TSX:TD)(NYSE:TD) stock and Royal Bank (TSX:RY)(NYSE:RY) stock both reported earnings on Thursday, beating earnings estimates.

Read more »

investment research
Bank Stocks

Royal Bank (TSX:RY) Raises Dividend: Time to Buy the Stock?

Royal Bank is giving investors another raise. Is the stock too cheap to ignore?

Read more »

Dividend Stocks

2 Canadian REITs on Sale: A Passive Landlord’s Dream Come True!

It's time for investors to explore Canadian REITs that are discounted and become passive landlords!

Read more »

Senior Man Sitting On Sofa At Home With Pet Labrador Dog
Dividend Stocks

Retirees: Top TSX Stocks to Earn Worry-Free Passive Income

These TSX stocks have consistently returned cash to their shareholders irrespective of the volatility and market conditions.

Read more »

Man making notes on graphs and charts
Dividend Stocks

Recession Stocks for Beginners

Recession-proof opportunities like Shaw Communications (TSX:SJR.B)(NYSE:SJR) should be on your watch list.

Read more »